OIFE Webinar: Update on clinical trials in osteogenesis imperfecta  
24 October 2023, 19:30-21:00 CET

A webinar with the goal of updating the OI-community about ongoing clinical trials in osteogenesis imperfecta, in adults and in children, including trials which are recruiting and others. Target group is anyone interested. Register here: https://forms.gle/krsjjo8RnvV2b6sj8

Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:30</td>
<td>Welcome and introduction</td>
</tr>
</tbody>
</table>
| 19:35 | Update on Orbit: Clinical Study to assess efficacy and safety of Setrusumab in individuals with Osteogenesis Imperfecta ages 5 – 26  
*Stan Krolczyk, Vice President Global Medical Affairs Strategy and Evidence Generation, Ultragenyx* |
| 19:50 | Update on Cosmic: Clinical Study to evaluate the effect of Setrusumab versus IV – Bisphosphonate in children with Osteogenesis Imperfecta  
*Stan Krolczyk, Vice President Global Medical Affairs Strategy and Evidence Generation, Ultragenyx* |
| 20:05 | Project SATURN - a Real-World Evidence & Data Collaboration with Existing European Datasets in Osteogenesis Imperfecta to Support Future Therapies  
*James Clancy, Senior Director, Clinical Operations, Mereo BioPharma* |
| 20:15 | POISE-1: TGF-β Antibody for the Treatment of Osteogenesis Imperfecta  
*Cemre Robinson, Clinical Research Director, Rare Bone Disease R&D, Sanofi* |
| 20:30 | TOPaZ, Treatment of Osteogenesis Imperfecta with Teriparatide and Zoledronic Acid Trial  
*Stuart Ralston, Professor of Rheumatology, University of Edinburgh, and Chief Investigator, TOPAZ Trial* |
| 20:45 | The BOOSTB4 Clinical Trial  
*Carlos Camozzi, MD, Medical Advisor, BOOST Pharma* |
| 20:55 | Summing up |
| 21:00 | End |

Read more about ongoing clinical trials at OIFE’s webpage.